PARP inhibitors for hereditary breast cancer with germline BRCA mutation

被引：0
|
作者：
Im, Seock-Ah [1 ]
机构：
[1] Seoul Natl Univ, Canc Res Inst, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.426
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PSY8-3
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [1] PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
    Menezes, Maria Clara Saad
    Raheem, Farah
    Mina, Lida
    Ernst, Brenda
    Batalini, Felipe
    [J]. CANCERS, 2022, 14 (17)
  • [2] PARP Inhibitors in Breast Cancer: BRCA and Beyond
    Rios, Jorge
    Puhalla, Shannon
    [J]. ONCOLOGY-NEW YORK, 2011, 25 (11): : 1014 - 1025
  • [3] Parp inhibitors for brca1/2mutation associated breast cancer
    Tutt, A. N. J.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [4] Implications of the type of BRCA1 germline mutation in the treatment of patients with hereditary breast cancer
    Vaclova, Tereza
    Woods, Nicholas T.
    Setien, Fernando
    Garcia Bueno, Jose Maria
    Antonio Macias, Jose
    Barroso, Alicia
    Urioste, Miguel
    Esteller, Manel
    Monteiro, Alvaro N. A.
    Benitez, Javier
    Osorio, Ana
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [5] PARP inhibitors in BRCA mutation-associated ovarian cancer
    Clamp, Andrew
    Jayson, Gordon
    [J]. LANCET ONCOLOGY, 2015, 16 (01): : 10 - 12
  • [6] A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome
    Wu, Yanmei
    Pan, Xiaodong
    Dou, Juan
    Zhang, Quan
    Li, Yuantong
    Sheng, Yuan
    Liu, Xishui
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
  • [7] PARP inhibitors as maintenance treatment for pancreatic cancer patients with germline BRCA mutations
    Kawecki, Maciej
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (03): : 190 - 193
  • [8] BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients
    Gari, Abdulrahim
    Rawas, Ghufran
    Mufti, Ahmad
    Elemam, Omima
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2021, 10 (03): : 33 - 49
  • [9] Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Goncalves, Anthony
    Lee, Kyung-Hun
    Fehrenbacher, Louis
    Yerushalmi, Rinat
    Mina, Lida A.
    Martin, Miguel
    Roche, Henri
    Im, Young-Hyuck
    Quek, Ruben G. W.
    Markova, Denka
    Tudor, Iulia C.
    Hannah, Alison L.
    Eiermann, Wolfgang
    Blum, Joanne L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (08): : 753 - 763
  • [10] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06): : 523 - 533
12345